Leading brokers name 3 ASX shares to buy today

Here’s why brokers rate these ASX shares as buys…

| More on:
ASX shares Business man marking buy on board and underlining it

Image Source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

With so many shares to choose from on the ASX, it can be hard to decide which ones to buy. The good news is that brokers across the country are doing a lot of the hard work for you.

Three top ASX shares leading brokers have named as buys this week are listed below. Here’s why they are bullish on them:

Allkem Ltd (ASX: AKE)

According to a note out of Bell Potter, its analysts have a buy rating and $17.53 price target on this lithium miner’s shares. Its analysts are positive on lithium prices and expect supply constraints to keep them higher for the foreseeable future. Bell Potter expects this to underpin significant improvements in cash generation and profits in the coming years. The broker also likes Allkem due to its aim of maintaining a 10% share of supply in a global lithium market experiencing unprecedented growth. The Allkem share price was trading at $9.80 on Monday.

Brambles Limited (ASX: BXB)

A note out of Ord Minnett reveals that its analysts have retained their buy rating and $13.50 price target on this logistics solutions company’s shares. Its analysts believe that the current Brambles share price implies an overly punitive earnings multiple of just 2x EBITDA on the company’s struggling Americas business. This compares to an estimated 12x EBITDA for its other businesses. So, with its Americas operations now starting to show early signs of a recovery, it could be a good time to invest. The Brambles share price is fetching $10.51 today.

Paradigm Biopharmaceuticals Ltd (ASX: PAR)

Another note out of Bell Potter reveals that its analysts have retained their buy rating but trimmed their price target on this biopharmaceutical company’s shares to $1.90. Bell Potter has reduced its valuation to reflect the ongoing correction to biotechnology sector valuations. However, it remains positive and believes upcoming data from the OA-008 osteoarthritis study could represent a significant catalyst. The Paradigm share price was trading at 98 cents on Monday.

Motley Fool contributor James Mickleboro has positions in Allkem Limited. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

Red buy button on an apple keyboard with a finger on it representing asx tech shares to buy today
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers are feeling positive about these ASX shares...

Read more »

A female broker in a red jacket whispers in the ear of a man who has a surprised look on his face as she explains which two ASX 200 shares should do well in today's volatile climate
Broker Notes

Experts say investors should buy these top blue chip ASX shares

Analysts are saying that these blue chip shares are in the buy zone…

Read more »

A scientist in a white coat and glasses puts her arms in the air in a sign of strength and success.
Healthcare Shares

Why this broker is tipping ‘strength in the CSL share price’

A leading broker is feeling positive about the CSL share price...

Read more »

Three happy miners.
Resources Shares

Broker sees 23% upside and a huge yield for BHP shares

BHP shares could offer the winning combination of strong gains and big dividends...

Read more »

Man looks shocked as he works on laptop on top a skyscraper with stockmarket figures in graphic behind him.
Broker Notes

9 ASX 200 shares now trading at ‘significant discounts’: broker

Top broker Goldman Sachs has revealed its top picks among the battered ASX 200 shares.

Read more »

Sad shopper sitting down with five shopping bags.
Retail Shares

What impacted ASX 200 retail shares this week?

With consumer confidence down substantially, one top broker has cut its share price targets for several ASX retail shares.

Read more »

Two excited mining workers in yellow high vis vests and hardhats shake hands to congratulate each other on a mineral discovery that is making the Galileo Mining share price rise today
Broker Notes

Guess which ASX 200 mining shares these experts are backing

These two ASX 200 shares are benefitting from Australia's current mining boom.

Read more »

A white and black clock face is shown with three hands saying Time to Buy reflecting Citi's view that it's time to buy ASX 200 banks
Broker Notes

Brokers name 3 ASX shares to buy today

Brokers are bullish on these ASX shares...

Read more »